trans-1-(4-Phenylcyclohexyl)-1-ethanon | 21060-31-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trans-1-(4-Phenylcyclohexyl)-1-ethanon
• 英文别名: trans-1-acetil-4-fenilcicloesano；trans-4-fenilacetilcicloesano；trans-4-phenyl-1-acetylcyclohexane；trans-1-Acetyl-4-phenyl-cyclohexan；trans-4-Phenyl-1-acetyl-cyclohexan；trans-4-Phenyl-acetylcyclohexan
• CAS: 21060-31-1
• 化学式: C₁₄H₁₈O
• 分子量: 202.296
• InChiKey: WADKHEBRFDWZCK-MQMHXKEQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.55
• 重原子数：
  15.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.07
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  trans-1-(4-Phenylcyclohexyl)-1-ethanon 在 aluminum (III) chloride 、 三氟甲磺酸三甲基硅酯 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors

  摘要：

  This Letter describes the discovery of a number of functionalized bisimidazoles bearing a cyclohexylphenyl, piperidylphenyl, or bicyclo[2,2,2]octylphenyl motif as HCV NS5A inhibitors. Compounds 2c, 4b and 6 have demonstrated low single-digit nM potency in gt-1a replicon and double-digit pM potency in gt-1b replicon, respectively. Moreover, both 4b and 6 have, respectively, exhibited good oral bioavailability in rats with a favorable liver/plasma ratio of the drug concentration. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.10.057
• 作为产物：
  描述：

  4-acetylcyclohexylbenzene 生成 trans-1-(4-Phenylcyclohexyl)-1-ethanon
  参考文献：
  名称：

  de Meglio; Ravenna; Carenini, Farmaco, Edizione Scientifica, 1982, vol. 37, # 12, p. 836 - 858

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE<br/>[FR] DÉRIVÉS D'AMINOTHIAZOLE SUBSTITUÉS, COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：TRANSTECH PHARMA INC

  公开号：WO2010025142A1

  公开（公告）日：2010-03-04

  Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.

  替代氨基噻唑衍生物，其制备方法，含有替代氨基噻唑的药物组合物，以及在治疗人类或动物疾病中的使用方法。这些化合物可能作为AgRP对黑色素皮质素受体作用的抑制剂而有用，因此可能有助于管理、治疗、控制或辅助治疗对黑色素皮质素受体调节敏感的疾病，包括与肥胖相关的疾病。
• Me₂(CH₂CH)SiCN: a bifunctional ethylene equivalent for Diels–Alder reaction based controllable tandem synthesis
  作者：Wen-Biao Wu、Bo-Shuai Mu、Jin-Sheng Yu、Jian Zhou

  DOI：10.1039/d2sc00147k

  日期：——

  equivalent for the Diels–Alder (DA) reaction. The use of this reagent enables the controllable synthesis of value-added cyclohexenyl ketones or 2-acyl cyclohexancarbonitrile derivatives through a five- or six-step tandem sequence based on a Wittig/cyanosilylation/DA reaction/retro-cyanosilylation/isomerization sequence that involves a temporary silicon-tethered intramolecular DA reaction.

  双功能甲硅烷基试剂 Me 2 (CH 2 CH)SiCN 已被开发为用于 Diels-Alder (DA) 反应的新型乙烯等价物。该试剂的使用能够通过基于 Wittig/氰基硅烷基化/DA 反应/逆氰基硅烷基化/异构化序列的五步或六步串联序列可控合成增值的环己烯基酮或 2-酰基环己腈衍生物，其中包括临时的硅束缚分子内 DA 反应。
• Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
  申请人：——

  公开号：US20040224954A1

  公开（公告）日：2004-11-11

  The invention relates to substituted (1H)quinoxalin-2-one compounds, methods for production thereof, medicaments containing said compounds and the use of said compounds for the production of medicaments. The invention further relates to substituted 4-aryl- and 4-heteroarylcyclohexane compounds and methods for production thereof.

  本发明涉及取代的(1H)喹喔啉-2-酮化合物，其制备方法，含有该化合物的药物以及使用该化合物制备药物的用途。本发明还涉及取代的4-芳基和4-杂环芳基环己烷化合物及其制备方法。
• Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use
  申请人：Mjalli Adnan M. M.

  公开号：US20100056587A1

  公开（公告）日：2010-03-04

  Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.

  替代氨噻唑衍生物，其制备方法，含有替代氨噻唑的药物组合物，以及在治疗人类或动物疾病中使用的方法。这些化合物可能有用作为AgRP对黑色素皮质素受体的作用抑制剂，因此可能有用于管理、治疗、控制或辅助治疗可能对黑色素皮质素受体调节敏感的疾病，包括与肥胖相关的疾病。
• INHIBITORS OF HCV NS5A
  申请人：Li Leping

  公开号：US20110237579A1

  公开（公告）日：2011-09-29

  The invention relates to non-macrocyclic, non-peptidic, substituted heterocyclic compounds useful for inhibiting hepatitis C virus (“HCV”) replication, particularly functions of the non-structural 5A (“NS5A”) protein of HCV

  本发明涉及一种非大环、非肽、取代杂环化合物，用于抑制丙型肝炎病毒（“HCV”）复制，特别是HCV的非结构蛋白5A（“NS5A”）蛋白的功能。